Emergency Intensive Care Ward, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Sci Rep. 2020 Dec 8;10(1):21489. doi: 10.1038/s41598-020-78607-5.
Noninvasive ventilation (NIV) is beneficial in acute respiratory failure (ARF) caused by chest trauma; however, NIV-related complications affect the efficacy. We evaluated whether NIV with helmet decreases the incidence of complications and improves its effects in a single center. Patients with ARF after chest trauma were randomized to receive NIV with helmet or face mask. The primary outcome was the rate of NIV-related complications. Secondary outcomes were PaO/FiO, patient's tolerance, intubation rate, length of intensive care unit (ICU) stay, and ICU mortality. The trial was terminated early after an interim analysis with 59 patients. The incidence of complications was lower in the helmet group [10% (3/29) vs 43% (13/30), P = 0.004], and PaO/FiOs were higher at 1 h and at the end of NIV (253.14 ± 64.74 mmHg vs 216.06 ± 43.86 mmHg, 277.07 ± 84.89 mmHg vs 225.81 ± 63.64 mmHg, P = 0.013 and 0.012) compared with them in face mask group. More patients reported excellent tolerance of the helmet vs face mask after 4 h of NIV [83% (24/29) vs 47% (14/30), P = 0.004] and at the end of NIV [69% (20/29) vs 30% (9/30), P = 0.03]. Differences in intubation rate, ICU stay, and mortality were non-significant (P = 0.612, 0.100, 1.000, respectively). NIV with helmet decreased NIV-related complications, increased PaO/FiO, and improved tolerance compared with NIV with face mask in patients with chest trauma.Trial registration: Registered in the Chinese Clinical Trial Registry (ChiCTR1900025915), a WHO International Clinical Trials Registry Platform ( http://www.chictr.org.cn/searchprojen.aspx ).
无创通气(NIV)有益于因胸部创伤导致的急性呼吸衰竭(ARF);然而,NIV 相关并发症会影响疗效。我们评估了在单中心中,使用头盔的 NIV 是否会降低并发症发生率并改善其效果。将胸部创伤后发生 ARF 的患者随机分为使用头盔或面罩进行 NIV。主要结局是 NIV 相关并发症的发生率。次要结局是 PaO/FiO、患者耐受性、插管率、重症监护病房(ICU)住院时间和 ICU 死亡率。在对 59 名患者进行中期分析后,试验提前终止。在头盔组中,并发症发生率较低[10%(3/29)与 43%(13/30),P=0.004],在 NIV 开始后 1 小时和结束时 PaO/FiO 较高[253.14±64.74 mmHg 与 216.06±43.86 mmHg,277.07±84.89 mmHg 与 225.81±63.64 mmHg,P=0.013 和 0.012]。与面罩组相比,在 NIV 开始后 4 小时和结束时,更多患者报告头盔的耐受性极好[83%(24/29)与 47%(14/30),P=0.004]。插管率、ICU 住院时间和死亡率无显著差异(P=0.612、0.100、1.000)。与面罩 NIV 相比,在胸部创伤患者中,头盔 NIV 可降低 NIV 相关并发症发生率、提高 PaO/FiO,并改善耐受性。
在中国临床试验注册中心(ChiCTR1900025915)注册,也是世界卫生组织国际临床试验注册平台(http://www.chictr.org.cn/searchprojen.aspx)的一部分。